Results 91 to 100 of about 320,592 (205)

The impact of antibodies to human glycoprotein CD4 and gamma-interferon on the t-cell immunity and the cytokine levels in patients co-infected with HIV/HCV during the antiretroviral therapy

Медицинский вестник Юга России, 2017
Objective: This work was to estimate the influence of antibodies to human glycoprotein CD4 and IFN-γ on the T-cell immunity and the cytokine levels in patients with HIV and HIV/HCV during the standard antiretroviral therapy.
A. V. Strygin, A. M. Docenko, A. O. Strygina, E. I. Morkovin, V. I. Petrov   +4 more
doaj   +1 more source

Combination anti-HIV antibodies provide sustained virological suppression. [PDF]

Nature, 2022
Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, Tolstenko J, McCormack G, Whitehead EJ, Schneck RF, Proschan MA, Benko E, Kovacs C, Oguz C, Seaman MS, Caskey M, Nussenzweig MC, Fauci AS, Moir S, Chun TW.   +19 more
europepmc   +1 more source

Enhancing antibodies in HIV infection

Parasitology, 1997
The author has summarized the history of discovery, the mechanism and the clinical significance of antibody-dependent enhancement (ADE) of HIV infection. ADE has two major forms: (a) complement-mediated antibody-dependent enhancement (C-ADE) and (b) complement-independent Fc receptor-dependent ADE (FcR-ADE).
openaire   +2 more sources

Antibody-mediated prevention and treatment of HIV-1 infection

Retrovirology, 2018
Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the evaluation of these antibodies in healthy and HIV-1-infected humans.
Henning Gruell, Florian Klein
doaj   +1 more source

Combination anti-HIV antibodies to achieve antiretroviral therapy-free virological suppression in infected individuals. [PDF]

Clin Transl Med, 2022
Rai MA, Chun TW.
europepmc   +1 more source

Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques

Nature Communications
The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear.
Sommer Holmes, Hui Li, Xiaoying Shen, Mitchell Martin, Ryan Tuck, Yue Chen, Elena E. Giorgi, Hélène Fradin Kirshner, Madison Berry, Elizabeth Van Italie, Sravani Venkatayogi, Joshua S. Martin Beem, Robert J. Edwards, Katayoun Mansouri, Ajay Singh, Cindy Kuykendall, Thaddeus Gurley, M. Anthony Moody, Nicole DeNayer, Todd Demarco, Thomas N. Denny, Yunfei Wang, Tyler D. Evangelous, John T. Clinton, Bhavna Hora, Kshitij Wagh, Michael S. Seaman, Kevin O. Saunders, Nicholas Solomotis, Johnathan Misamore, Mark G. Lewis, Kevin Wiehe, David C. Montefiori, George M. Shaw, Wilton B. Williams   +34 more
doaj   +1 more source

Passive and active antibody studies in primates to inform HIV vaccines

Expert Review of Vaccines, 2018
Introduction: Prevention of infection remains the ultimate goal for HIV vaccination, and there is compelling evidence that antibodies directed to Envelope are necessary to block infection.
Ann J. Hessell, Delphine C. Malherbe, Nancy L. Haigwood   +2 more
doaj   +1 more source

Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies. [PDF]

PLoS Pathog, 2023
Joyce C, Murrell S, Murrell B, Omorodion O, Ver LS, Carrico N, Bastidas R, Nedellec R, Bick M, Woehl J, Zhao F, Burns A, Barman S, Appel M, Ramos A, Wickramasinghe L, Eren K, Vollbrecht T, Smith DM, Kosakovsky Pond SL, McBride R, Worth C, Batista F, Sok D, IAVI Protocol C Investigators & The IAVI African HIV Research Network, Poignard P, Briney B, Wilson IA, Landais E, Burton DR.   +29 more
europepmc   +1 more source

Is an HIV vaccine possible?

Brazilian Journal of Infectious Diseases
The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult over the ensuing twenty years. Most vaccines are developed by inducing neutralizing antibodies against the target pathogen or by using attenuated strains of
Nancy A. Wilson, David I. Watkins
doaj   +1 more source

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. [PDF]

, 2018
A clinical trial was performed to evaluate 3BNC117, a potent anti-HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI).
Barton, John P, Belblidia, Shiraz A, Burke, Leah, Butler, Allison L, Caskey, Marina, Cohen, Yehuda Z, Dizon, Juan P, Gulick, Roy M, Jankovic, Mila, Krassnig, Lisa, Lorenzi, Julio CC, Lu, Ching-Lan, Mendoza, Pilar, Millard, Katrina, Nussenzweig, Michel C, Oliveira, Thiago Y, Pai, Joy, Seaman, Michael S, Shimeliovich, Irina, Sleckman, Christopher, Witmer-Pack, Maggi   +20 more
core   +1 more source